It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Human T-cell leukemia virus type 1 (HTLV-1) is a retrovirus that causes adult T-cell leukemia/lymphoma (ATL), a cancer of infected CD4+ T-cells. There is both sense and antisense transcription from the integrated provirus. Sense transcription tends to be suppressed, but antisense transcription is constitutively active. Various efforts have been made to elucidate the regulatory mechanism of HTLV-1 provirus for several decades; however, it remains unknown how HTLV-1 antisense transcription is maintained. Here, using proviral DNA-capture sequencing, we found a previously unidentified viral enhancer in the middle of the HTLV-1 provirus. The transcription factors, SRF and ELK-1, play a pivotal role in the activity of this enhancer. Aberrant transcription of genes in the proximity of integration sites was observed in freshly isolated ATL cells. This finding resolves certain long-standing questions concerning HTLV-1 persistence and pathogenesis. We anticipate that the DNA-capture-seq approach can be applied to analyze the regulatory mechanisms of other oncogenic viruses integrated into the host cellular genome.
Human T-cell leukemia virus type 1 (HTLV-1) is an oncogenic virus with constantly active antisense transcription from the proviral genome. Here, Matsuo et al. perform proviral DNA-capture followed by high-throughput sequencing and identify a yet unknown viral enhancer in the middle of the HTLV-1 provirus.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 Joint Research Center for Human Retrovirus Infection, Kumamoto University, Division of Genomics and Transcriptomics, Kumamoto, Japan (GRID:grid.274841.c) (ISNI:0000 0001 0660 6749); International Research Center for Medical Sciences (IRCMS), Kumamoto University, Kumamoto, Japan (GRID:grid.274841.c) (ISNI:0000 0001 0660 6749)
2 Kansai Medical University, Department of Microbiology, Osaka, Japan (GRID:grid.410783.9) (ISNI:0000 0001 2172 5041)
3 Faculty of Life Sciences, Kumamoto University, Department of Microbiology, Kumamoto, Japan (GRID:grid.274841.c) (ISNI:0000 0001 0660 6749)
4 Joint Research Center for Human Retrovirus Infection, Kumamoto University, Division of Genomics and Transcriptomics, Kumamoto, Japan (GRID:grid.274841.c) (ISNI:0000 0001 0660 6749)
5 Joint Research Center for Human Retrovirus Infection, Kumamoto University, Division of Genomics and Transcriptomics, Kumamoto, Japan (GRID:grid.274841.c) (ISNI:0000 0001 0660 6749); International Research Center for Medical Sciences (IRCMS), Kumamoto University, Kumamoto, Japan (GRID:grid.274841.c) (ISNI:0000 0001 0660 6749); HIV Dynamics and Replication Program, National Cancer Institute, Viral Recombination Section, Frederick, US (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075)
6 Joint Research Center for Human Retrovirus Infection, Kumamoto University, Division of Genomics and Transcriptomics, Kumamoto, Japan (GRID:grid.274841.c) (ISNI:0000 0001 0660 6749); Respiratory Medicine and Oncology, Saga University, Division of Hematology, Saga, Japan (GRID:grid.412339.e) (ISNI:0000 0001 1172 4459)
7 Imamura General Hospital, Department of Hematology, Kagoshima, Japan (GRID:grid.410783.9)
8 Rheumatology and Infectious Disease, Kumamoto University Hospital, Department of Hematology, Kumamoto, Japan (GRID:grid.411152.2) (ISNI:0000 0004 0407 1295); Cancer Center, Kumamoto University Hospital, Kumamoto, Japan (GRID:grid.411152.2) (ISNI:0000 0004 0407 1295)
9 Faculty of Life Sciences, Kumamoto University, Division of Informative Clinical Sciences, Kumamoto, Japan (GRID:grid.274841.c) (ISNI:0000 0001 0660 6749)
10 Imamura General Hospital, Department of Hematology, Kagoshima, Japan (GRID:grid.274841.c); Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan (GRID:grid.258333.c) (ISNI:0000 0001 1167 1801)